Merck Inc., known as MSD outside of the United States and Canada, announced results from STRIDE-3, a Phase III trial evaluating V 116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new and updated results from the Phase II CAPTIVATE study evaluating Imbruvica (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) .
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission granted marketing authorisation for the expanded use of Imbruvika (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL).